Zura Bio Ltd Ordinary Shares - Class A ZURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
-
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
-
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Trading Information
- Previous Close Price
- $3.68
- Day Range
- $3.51–3.72
- 52-Week Range
- $1.00–7.44
- Bid/Ask
- $3.25 / $3.77
- Shares Outstanding
- 95.00M
- Market Cap
- $333.51M
- Volume/Avg
- 129 / 729,170
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 40
- Website
- https://www.zurabio.com
Valuation
|
Metric
|
ZURA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.62 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ZURA
|
|---|---|
Quick Ratio | 19.21 |
Current Ratio | 19.33 |
Interest Coverage | — |
Quick Ratio
ZURA
Profitability
|
Metric
|
ZURA
|
|---|---|
Return on Assets (Normalized) | −37.75% |
Return on Equity (Normalized) | −44.64% |
Return on Invested Capital (Normalized) | −46.41% |
Return on Assets
ZURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Thhwdgpl | Bdzfft | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lbtkbpdm | Dwyxgs | $64B | |||
| argenx SE ADR
ARGX
| Nkmmwnjxc | Lsvl | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nzypkkrx | Tdwssm | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Wxpmymgxc | Djbrpy | $24B | |||
| BioNTech SE ADR
BNTX
| Xjdxpzpl | Nymqs | $23B | |||
| Incyte Corp
INCY
| Bvtnzfgv | Cxbks | $22B | |||
| Moderna Inc
MRNA
| Zvjchrjkn | Pfzk | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rbnqjglh | Xjbtc | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Qdgjkdk | Pty | $13B |
United States